Navigation Links
T-beta-RIII joins the fight against breast cancer

Although the soluble factor TGF-beta has been shown to suppress the growth of tumor cells in the early stages of breast cancer, high levels of TGF-beta during the later stages of the disease are associated with a poor outcome. A study using human breast cancer samples and mice, which appears online on December 7 in advance of publication in the January print issue of the Journal of Clinical Investigation, indicates that changes in expression of one component of the TGF-beta receptor, T-beta-RIII, might provide a mechanism for the distinct effects of TGF-beta at the different stages of breast cancer.

Gerard Blobe and colleagues from Duke University showed that expression of T-beta-RIII by human breast cancer samples markedly decreased or was lost with disease progression. Conversely, in a mouse model of breast cancer, tumor cells engineered to express high levels of T-beta-RIII were less able to invade the breast tissue and to metastasize to other organs than tumor cells not engineered to express this protein. Further analysis revealed that the mechanism behind these protective effects of T-beta-RIII was likely to be T-beta-RIII cleavage at the cell membrane, which releases soluble T-beta-RIII that blocks TGF-beta signaling. As low levels of T-beta-RIII were found to be associated with decreased recurrence-free survival of patients with breast cancer and loss of T-beta-RIII was found to begin before tumors became invasive, the authors suggest that analysis of T-beta-RIII levels might help clinicians decide how aggressively to treat their patients.
'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. New Rotavirus vaccine joins routine infant immunization schedule
2. Learning to fight an adversary that wont stay down
3. Antibiotic might fight HIV-induced neurological problems
4. NYU study reveals how brains immune system fights viral encephalitis
5. Molecular models advance the fight against malaria
6. Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries
7. Researchers find promising cancer-fighting power of synthetic cell-signaling molecule
8. Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma
9. Two chemicals boost immune cells ability to fight HIV without gene therapy
10. Experiment station researchers to explore genome of disease-fighting fungus
11. Bacterial genome sheds light on synthesizing cancer-fighting compounds
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading ... announced that its board of directors has amended its shareholder rights ... 27, 2017 to March 27, 2018. The amendment was not in response ... ... Biotech Ltd. is a China -based biopharmaceutical company ...
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Global Markets" report to their offering. ... The Global Market ... Billion in 2016 at a CAGR of 8.9%, ... and non-energetic bioproducts into seven major product segments: bio-derived chemicals, ...
Breaking Biology Technology: